New study investigates GLP-1RA impact on Women's muscle and bone health
NCT ID NCT07422987
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This study looks at how estrogen levels influence body composition and muscle function in midlife women (ages 35-60) who are starting a GLP-1RA medication for weight loss. Researchers will measure changes in weight, muscle mass, bone density, and strength over time. The goal is to understand whether estrogen plays a role in how these drugs affect lean mass and bone health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BODY COMPOSITION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?